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To the Editor: 
 
Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical 
coronary stenosis in patients with STEMI 
 
Von Willebrand factor (VWF) mediates platelet adhesion and agglutination at sites of 
vascular injury. VWF is a large multimeric glycoprotein, which circulates in a coiled, non-
adhesive conformation. When exposed to high shear stress, VWF unfolds and elongates 
to highly adhesive multimer strands that adhere on exposed collagen fibers and – by 
interacting with platelet glycoprotein Ib-alpha – recruit platelets to the injury site.1,2 
 
Recent in vivo work showed that transition from laminar to turbulent flow, as observed at 
sites of stenotic vessels, is the most important trigger for adhesive conformational change 
of VWF.3 Additionally, VWF’s ability to tether platelets is directly proportional to its 
multimeric size. The latter is regulated by ADAMTS13, a metalloprotease that cleaves 
VWF multimers within the unfolded A2 domain, thereby reducing VWF multimer size, and 
by this, decreasing VWF adhesiveness.4 
 
We postulated that transition from laminar to turbulent flow at sites of critical coronary 
stenosis may cause a local imbalance between VWF and ADAMTS13,5 which would be 
responsible for the presence of highly adhesive VWF multimers mediating platelet 
adhesion and agglutination, ultimately responsible for acute occlusion. The aim of this 
investigation was to evaluate systemic and intracoronary thrombin generation, VWF and 
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ADAMTS13 activity in patients with acute coronary syndromes (ACS) with angiographic 
evidence of acute thrombotic coronary occlusion. 
 
We investigated 27 patients (24 men; age median 65 years, IQR 54 – 74, range 41 – 84) 
undergoing emergency cardiac catheterization for hemodynamically stable ACS 
presenting with ST-elevation myocardial infarction (STEMI) who gave written informed 
consent. The culprit lesion was determined angiographically in two orthogonal projections 
and was defined by the combination of: i) abrupt (typical) vessel occlusion; and ii) 
complete absence of (or severely impaired) peripheral coronary flow. Infarct localization 
was anterior in 9 patients, infero-posterior in 16 and lateral in two. Maximal CK value was 
median 1440 U/l (IQR 922 – 2262, range 750 – 5’800) and the extent of the underlying 
coronary artery disease assessed by the Syntax score was 17±7. All patients underwent 
PCI/stenting with a median time from chest pain to onset-balloon of 105 minutes (IQR 62 – 
150, range 20 – 1’140). 
 
Blood samples were obtained at three different sites before stenting: from the femoral vein 
and at the ostia of the right or left coronary artery through a coronary guiding 6 french 
catheter, and 1-3 cm distal to the site of occlusion with a conventional 6 french compatible 
thrombus aspiration catheter advanced through the lesion. In a preliminary phase we 
verified that blood sampling by coronary catheter did not alter results for thrombin-
generation markers, VWF, and ADAMTS13 compared to peripheral venipuncture. 
Additionally, care was taken to perform extra slow aspiration to avoid turbulences inside 
the catheter. Samples were collected into citrate test tubes, snap-frozen immediately after 
centrifugation, and kept at -80°C till batch-analysis. Markers of thrombin generation and 
VWF antigen were assessed by ELISA and VWF activity by a turbidimetric method as 
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published.6  ADAMTS13 activity was measured by the FRETS-VWF73 assay as previously 
described.7 
 
Our results show that parameters of thrombin generation, i.e. prothrombin fragments 1+2 
(F1+2), thrombin-antithrombin complexes (TAT), and D-dimers did not differ between 
peripheral and coronary blood (Table 1). This excludes major preanalytical artifacts and 
appears to reflect a modest contribution of thrombin generation to acute coronary 
occlusion.8 
 
In line with previous reports in ACS patients, we observed markedly increased circulating 
levels of VWF and a relative reduction in systemic ADAMST13 activity.9-11 Most 
interestingly and to our knowledge for the first time, we documented a significantly reduced 
ADAMTS13 activity in coronary blood compared to systemic levels and a significant 
gradient of both VWF activity (VWF:RCo) and antigen (VWF:Ag) across the coronary 
occlusion (Table 1 and Figure 1). 
 
These data suggest a pathogenic role for an acquired intracoronary ADAMTS13 deficiency 
in ACS and indicate that VWF is retained at the site of acute coronary occlusion. In 
particular, our data support the hypothesis that a decreased ADAMTS13 / VWF ratio in the 
coronary flow favors the presence of highly adhesive VWF multimers that would deposit at 
the site of a critical stenosis, mediating platelet adhesion and agglutination and, eventually, 
leading to coronary occlusion. In fact, histological examination of coronary thrombi 
aspirated from patients with acute myocardial infarction revealed a prominent co-
localization of VWF with platelets.12,13 These observations are in line with animal models 
showing that ADAMTS13 deficiency exacerbates VWF-dependent thrombus formation on 
disrupted plaques, thereby impacting also on the resulting infarct size.14,15 A surprising 
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finding was the significantly reduced ADAMTS13 activity in coronary blood compared to 
systemic levels. Although we do not know the reason for this difference, we speculate that 
it might be explained by local hemodynamic factors (wide flow variations within cardiac 
chambers followed by low pressure, high velocity intracoronary flow) and/or changes 
secondary to the acute coronary occlusion (increased proximal coronary flow resistance 
and intracoronary shear stress because of vascular bed’s amputation).  
 
In conclusion, our observations support the hypothesis that a significantly reduced 
ADAMTS13 / VWF ratio in the coronary artery flow plays a pathogenic role in ACS and 
suggest that transition from laminar to turbulent flow at sites of coronary stenosis further 
enhances VWF activation and deposition. These events would ultimately sustain platelet 
adhesion and agglutination, and favor coronary occlusion. 
 
The potential therapeutic implication of this concept, to be clinically tested, would be the 
local infusion of ADAMTS13 to decrease VWF-mediated platelet adhesion and 
agglutination at sites of critical coronary stenosis.   
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Table 1. Von Willebrand factor, ADAMTS13, and markers of thrombin generation in patients with an acute coronary syndrome 
 
Parameter  Peripheral venous blood Coronary blood, 
pre occlusion 
Coronary blood, 
post occlusion 
p-value 1 
      
 unit median IQR median IQR median IQR  
         
VWF:RCo   % 184 114 – 277 190 124 – 263 146 * 106 – 236 0.003 
         
VWF:Ag % 167 115 – 248 157 119 – 207 137 * 99 – 192 <0.001 
         
VWF:RCo / 
VWF:Ag 
ratio 1.06 0.95 – 1.23 1.13 0.97 – 1.34 1.10 0.99 – 1.30 0.540 
         
ADAMTS13 % 75 67 – 85 53 † 31 – 75 48 † 39 – 68 <0.001 
         
ADAMTS13 / 
VWF:RCo 
ratio 0.48 0.24 – 0.65 0.31 † 0.15 – 0.46 0.29 † 0.19 – 0.49 <0.001 
         
F1+2 pmol/ml 177 106 – 280 135 105 – 264  159 117 – 237  0.190 
         
TAT ng/ml 5.9 3.4 – 12.4  4.3 2.9 – 6.7 5.1 3.9 – 9.6 0.065 
         
D-dimers ng/ml 397 194 – 665  393 219 – 963 417 239 – 1097 0.468 
 
 
Legend : 
F1+2, prothrombin fragments 1+2; TAT, thrombin-antithrombin complexes; VWF, von Willebrand factor; VWF:Ag, VWF:antigen; VWF:RCo, VWF 
ristocetin cofactor activity. 
 
1
 Statistical analysis by Friedman repeated measures ANOVA on ranks, all pair-wise comparison procedure (Tukey test), n=27. 
 
* Statistically significantly different from peripheral blood and pre occlusion coronary blood 
† Statistically significantly different from peripheral blood   
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Figure 1. Von Willebrand factor, ADAMTS13, and markers of thrombin generation in 
patients with an acute coronary syndrome 
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Legend: See text for details. Panels A and B: ADAMTS13 activity. Panels C and D: Von Willebrand 
factor activity (VWF:RCo). Panels E and F: Von Willebrand factor antigen (VWF:Ag) 
A B 
E 
C D 
F 
8 
 
References 
 
1. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor 
multimers: focus on high-molecular-weight multimers and their role in hemostasis. 
Blood Coagul Fibrinolysis. 2014;25(3):206-216. 
2. Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. 
Cell Mol Life Sci. 2015;72(2):307-326. 
3. Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood. 
2014;124(9):1412-1425. 
4. Reininger AJ. The function of ultra-large von Willebrand factor multimers in high shear 
flow controlled by ADAMTS13. Hamostaseologie. 2015;35(3):225-233. 
5. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor 
regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 2004;126(2):213-
218. 
6. Zürcher M, Sulzer I, Barizzi G, Lämmle B, Alberio L. Stability of coagulation assays 
performed in plasma from citrated whole blood transported at ambient temperature. 
Thromb Haemost. 2008;99(2):416-426. 
7. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and 
relapse in patients with thrombotic thrombocytopenic purpura. Blood. 
2010;115(8):1500-1511; quiz 1662. 
8. Srikanth S, Ambrose JA. Pathophysiology of coronary thrombus formation and 
adverse consequences of thrombus during PCI. Curr Cardiol Rev. 2012;8(3):168-176. 
9. Horii M, Uemura S, Uemura M, et al. Acute myocardial infarction as a systemic 
prothrombotic condition evidenced by increased von Willebrand factor protein over 
ADAMTS13 activity in coronary and systemic circulation. Heart Vessels. 
2008;23(5):301-307. 
10. Bongers TN, de Bruijne EL, Dippel DW, et al. Lower levels of ADAMTS13 are 
associated with cardiovascular disease in young patients. Atherosclerosis. 
2009;207(1):250-254. 
11. Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in 
arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 
2014;28(4):167-178. 
12. Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S. Co-localization of von 
Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and 
consistent presence of inflammatory cells in coronary thrombi obtained by an 
aspiration device from patients with acute myocardial infarction. J Thromb Haemost. 
2006;4(1):114-120. 
13. Yamashita A, Sumi T, Goto S, et al. Detection of von Willebrand factor and tissue 
factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. Am J 
Cardiol. 2006;97(1):26-28. 
14. Moriguchi-Goto S, Yamashita A, Tamura N, et al. ADAMTS-13 attenuates thrombus 
formation on type I collagen surface and disrupted plaques under flow conditions. 
Atherosclerosis. 2009;203(2):409-416. 
15. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency 
exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. 
Blood. 2012;120(26):5224-5230. 
 
